Iovance Biotherapeutics SG&A Expenses 2010-2024 | IOVA

Iovance Biotherapeutics sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Iovance Biotherapeutics SG&A Expenses 2010-2024 | IOVA

Iovance Biotherapeutics sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.3B
Vertex Pharmaceuticals (VRTX)$122B
Bristol Myers Squibb (BMY)$112.5B
Gilead Sciences (GILD)$111.9B
Regeneron Pharmaceuticals (REGN)$91.4B
CSL (CSLLY)$90.8B
GSK (GSK)$76.6B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$34.8B
BioNTech SE (BNTX)$25.9B
Biogen (BIIB)$25.3B
Illumina (ILMN)$24.5B
Moderna (MRNA)$20.6B
BeiGene (BGNE)$20.2B
Genmab (GMAB)$15.1B
Incyte (INCY)$14.6B
Exact Sciences (EXAS)$13.1B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.2B
Bio-Techne Corp (TECH)$12B
Vaxcyte (PCVX)$11.9B
Sarepta Therapeutics (SRPT)$11.7B
QIAGEN (QGEN)$10B
Exelixis (EXEL)$9.8B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.5B
Legend Biotech (LEGN)$8B
Repligen (RGEN)$7.8B